{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:22:16Z","timestamp":1790922136437,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.urolonc.2024.06.026","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T14:41:23Z","timestamp":1722004883000},"page":"451.e1-451.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Mitomycin C vs. Bacillus Calmette\u2013Guerin for treatment of intermediate-risk nonmuscle invasive bladder cancer patients\u2014A comparative analysis from a single center"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6126-9889","authenticated-orcid":false,"given":"Pietro","family":"Scilipoti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Longoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"de Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Cannoletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusy","family":"Burgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Lucian\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Rosiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Gandaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Salonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2024.06.026_bib0001","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on non\u2013muscle-invasive bladder cancer (TA, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.06.026_bib0002","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.juro.2014.02.2573","article-title":"Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancer","volume":"192","author":"Kamat","year":"2014","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.06.026_bib0003","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00345-021-03908-x","article-title":"Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage","volume":"40","author":"Balasubramanian","year":"2022","journal-title":"World J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.06.026_bib0004","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.euf.2021.03.016","article-title":"Intravesical therapy in patients with intermediate-risk non\u2013muscle-invasive bladder cancer: a systematic review and network meta-analysis of disease recurrence","volume":"8","author":"Laukhtina","year":"2022","journal-title":"European Urology Focus"},{"issue":"5","key":"10.1016\/j.urolonc.2024.06.026_bib0005","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.euo.2022.05.005","article-title":"Intermediate-risk non\u2013muscle-invasive bladder cancer: updated consensus definition and management recommendations from the international bladder cancer group","volume":"5","author":"Tan","year":"2022","journal-title":"European Urology Oncology"},{"issue":"3","key":"10.1016\/j.urolonc.2024.06.026_bib0006","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance Bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk TA, T1 Papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.06.026_bib0007","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.eururo.2014.06.024","article-title":"Guidelines for reporting of statistics in european urology","volume":"67","author":"Vickers","year":"2015","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.026_bib0008","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research","volume":"15","author":"Chesnaye","year":"2022","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1016\/j.urolonc.2024.06.026_bib0009","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.euo.2023.12.008","article-title":"Comparative effectiveness of neoadjuvant pembrolizumab versus cisplatin-based chemotherapy or upfront radical cystectomy in patients with muscle-invasive urothelial bladder cancer","volume":"7","author":"Li","year":"2024","journal-title":"European urology oncology"},{"issue":"4","key":"10.1016\/j.urolonc.2024.06.026_bib0010","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.026_bib0011","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"B\u00f6hle","year":"2003","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.026_bib0012","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin versus mitomycin C for Ta and T1 bladder cancer","volume":"1","author":"Schmidt","year":"2020","journal-title":"The Cochrane Library"},{"issue":"2","key":"10.1016\/j.urolonc.2024.06.026_bib0013","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An Individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin c versus bacillus Calmette-Gu\u00e9rin for non\u2013muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.urolonc.2024.06.026_bib0014","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jnci\/93.8.597","article-title":"Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial","volume":"93","author":"Au","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.026_bib0015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s002800050448","article-title":"ThioTEPA pharmacokinetics during intravesical chemotherapy: the influence of dose and volume of instillate on systemic uptake and dose rate to the tumour","volume":"38","author":"Masters","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.026_bib0016","first-page":"139","article-title":"Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine","volume":"4","author":"Gao","year":"1998","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.urolonc.2024.06.026_bib0017","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.eururo.2008.01.015","article-title":"The schedule and duration of intravesical chemotherapy in patients with non\u2013muscle-invasive bladder cancer: a systematic review of the published results of randomized clinical trials","volume":"53","author":"Sylvester","year":"2008","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.06.026_bib0018","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.eururo.2009.04.009","volume":"56","author":"J\u00e4rvinen","year":"2009","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.06.026_bib0019","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.eururo.2007.02.063","article-title":"Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Gu\u00e9rin (bcg) in patients with non\u2013muscle-invasive bladder carcinoma","volume":"52","author":"Friedrich","year":"2007","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.06.026_bib0020","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.026_bib0021","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.euo.2022.10.008","article-title":"Hyperthermic mitomycin C in intermediate-risk non\u2013muscle-invasive bladder cancer: results of the HIVEC-1 trial","volume":"6","author":"Angulo","year":"2023","journal-title":"European Urology Oncology"},{"issue":"4","key":"10.1016\/j.urolonc.2024.06.026_bib0022","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1464-410X.2006.06706.x","article-title":"Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and Bacillus Calmette-Gu\u00e9rin in patients with high-risk bladder cancer","volume":"99","author":"G\u00e5rdmark","year":"2007","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.urolonc.2024.06.026_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211721","article-title":"Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non\u2013muscle-invasive bladder cancer and with low and intermediate EORTC-risk score","volume":"14","author":"Simon","year":"2019","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.urolonc.2024.06.026_bib0024","first-page":"194","article-title":"First and second transurethral resections in intermediate-high risk bladder cancer: Impact of the surgeon's volume on the recurrence and progression of primary bladder cancer","volume":"68","author":"Del Zingaro","year":"2016","journal-title":"Minerva Urol Nefrol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.026_bib0025","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000520630","article-title":"Electromotive drug administration of mitomycin c (EMDA\/MMC) versus intravesical immunotherapy with Bacillus Calmette-Gu\u00e9rin (BCG) in intermediate and high risk non muscle invasive bladder cancer","volume":"107","author":"Zazzara","year":"2021","journal-title":"Urol Int"},{"issue":"1","key":"10.1016\/j.urolonc.2024.06.026_bib0026","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/03915603231206603","article-title":"Comparative study between mitomycin C versus Bacillus Calmette-Gu\u00e9rin (BCG) in high-risk non-muscle-invasive bladder cancer","volume":"91","author":"Zaza","year":"2023","journal-title":"Urologia Journal"},{"issue":"4","key":"10.1016\/j.urolonc.2024.06.026_bib0027","first-page":"167","article-title":"A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy","volume":"80","author":"Mangiarotti","year":"2008","journal-title":"PubMed."},{"key":"10.1016\/j.urolonc.2024.06.026_bib0028","first-page":"157","article-title":"Managing the adverse events of intravesical bacillus Calmette-Guérin therapy","volume":"7","author":"Decaestecker","year":"2015","journal-title":"Research and Reports in Urology"},{"issue":"18","key":"10.1016\/j.urolonc.2024.06.026_bib0029","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/BF03262330","article-title":"The health economics of bladder cancer","volume":"21","author":"Botteman","year":"2003","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.urolonc.2024.06.026_bib0030","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/bju.15571","article-title":"Intravesical mitomycin C (MMC) and MMC\u202f+\u202fcytosine arabinoside for non-muscle-invasive bladder cancer: a randomised clinical trial","volume":"129","author":"Miyata","year":"2021","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.urolonc.2024.06.026_bib0031","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/j.1464-410X.2010.09654.x","article-title":"Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC)","volume":"107","author":"Colombo","year":"2010","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.urolonc.2024.06.026_bib0032","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0849","article-title":"Comparison of sequential intravesical gemcitabine and docetaxel vs Bacillus Calmette-Gu\u00e9rin for the treatment of patients with high-risk non\u2013muscle-invasive bladder cancer","volume":"6","author":"McElree","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"7","key":"10.1016\/j.urolonc.2024.06.026_bib0033","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncology"},{"issue":"12","key":"10.1016\/j.urolonc.2024.06.026_bib0034","doi-asserted-by":"crossref","first-page":"485.e1","DOI":"10.1016\/j.urolonc.2023.06.017","article-title":"Sequential intravesical gemcitabine and docetaxel for treatment-na\u00efve and previously treated intermediate-risk nonmuscle invasive bladder cancer","volume":"41","author":"McElree","year":"2023","journal-title":"Urol Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.06.026_bib0035","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.euo.2023.06.011","article-title":"Sequential intravesical gemcitabine and docetaxel is an alternative to Bacillus Calmette-Gu\u00e9rin for the treatment of intermediate-risk non\u2013muscle-invasive bladder cancer","volume":"6","author":"Tan","year":"2023","journal-title":"Eur Urol Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924005386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924005386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T08:33:41Z","timestamp":1731746021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924005386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1078143924005386"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.06.026","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mitomycin C vs. Bacillus Calmette\u2013Guerin for treatment of intermediate-risk nonmuscle invasive bladder cancer patients\u2014A comparative analysis from a single center","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.06.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}